Summary In this study, we have investigated the expression of the proto-oncogene c-erbB2 in a total of 70 human primary breast tumours. In agreement with other workers, we observed c-erbB2 gene amplification in 17.5% of the tumours studied. In addition, we carried out a comprehensive analysis of c-erbB2 mRNA expression in the tumours using RNase mapping and in situ hybridisation techniques. Our results indicated a more frequent (30%) overexpression of c-erbB2 mRNA, which was associated only with breast carcinomas of a ductal origin. Furthermore, analysis of the c-erbB2 mRNA gene locus in the same tumours demonstrated that enhanced c-erbB2 expression could occur in the presence or absence of gene amplification, suggesting that additional molecular mechanisms may result in overexpression of c-erbB2 mRNA in human mammary tumours. In situ hybridisation showed that elevated levels of c-erbB2 mRNA were specific to malignant cells within the breast tumour. Analysis of the association between c-erbB2 mRNA overexpression and clinicopathological factors revealed a significant correlation with poor tumour grade, but not with steroid receptor status or patient menopausal status. No significant correlation was observed between overexpression of c-erbB2 mRNA and early disease recurrence in our group of patients, although there was a definite trend towards poorer prognosis.
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Recent efforts in cancer research have been directed at finding molecular markers of potential predictive value in tumour prognosis. There is increasing evidence to link the activation of cellular proto-oncogenes with the initiation or progression of particular human malignancies. In human breast carcinoma, several such genes have been found to be amplified or rearranged, including c-myc and c-ras (Whittaker et al., 1986; Escot et al., 1986) , although the role of these proto-oncogenes in the progression of the disease is, as yet, unclear.
There is at present much controversy surrounding the potential role of the human proto-oncogene c-erbB2 (also known as neu or HER2) in breast cancer prognosis (Ali et al., 1988a; Slamon & Clark, 1988) . C-erbB2 is related to, but distinct from, the c-erbBl/EGF receptor gene (Bargmann et al., 1986; Yamamoto et al., 1986 ) and maps to band q21 on chromosone 17 (Fukushige et al., 1986; Coussens et al., 1985) . It encodes a normal cellular glycoprotein showing structural features of a growth factor receptor, including a transmembrane region and a tyrosine kinase domain , although its ligand has not yet been identified. Many tissues express c-erbB2 transcripts. However, observations that amplifications of the c-erbB2 gene is limited to carcinomas of glandular epithelial origin (Yokota et al., 1986) have led to the suggestion that the c-erbB2 gene encodes a growth factor receptor associated with glandular epithelium (Zhou et al., 1987) .
The c-erbB2 gene is amplified relatively frequently in human primary breast carcinomas, although the frequency and level of amplification observed in different studies varies widely, in the range 10-40% (Slamon et al., 1987; Van de Vijver et al., 1987; Venter et al., 1987; Ali et al., 1988b; Berger et al., 1988) . Clinical interest in the c-erbB2 gene with respect to breast cancer prognosis has been stimulated by the reports of Slamon et al. (1987) and Varley et al. (1987) that amplification of the c-erbB2 gene is a significant predictor of decreased survival time and rapid relapse in patients. Slamon et al. (1987) reported that c-erbB2 amplification had greater prognostic significance than most currently used indicators in lymph node-positive disease. However, recent primary breast tumour DNA studies by other groups (Zhou et al., 1987 (Zhou et al., , 1989 Ali et al., 1988a,b) DNA was extracted from the peripheral blood lymphocytes of breast tumour patients by the method of Jeanpierre (1987) . Probes C-erbB2 The plasmid pSV2-erbB2, which contains a full length c-erbB2 cDNA clone in the vector pSV2 hardt's solution, 0.5% SDS and 500gigml-' of denatured sonicated salmon sperm DNA. The blot was then washed to high stringency (0.5 x SSC at 65°C) and autoradiographed for 1-3 days at -70°C using Kodak X-Omat XAR5 film. Blots were stripped of probe by submerging in boiling water for 5 min and were pre-hybridised and re-hybridised, using a second labelled probe, as before. 21, 42, 70, 69, 117, 106, 59, 94, 112) . Normal human lymphocyte DNA was analysed in parallel on each gel as a control for levels of single copy c-erbB2.
In order to control for slight differences in loading of tumour DNA and for DNA degradation, all filters were stripped of the c-erbB2 probe and rehybridised with D5S6, a single copy genomic DNA probe from chromosome 5. D5S6 hybridises to DNA fragments of 11 kb, 9 kb and 7.5 kb and therefore provides a suitable marker for the amount of high molecular weight DNA present in each track. The relative intensity of this signal in each tumour track was used to normalise the autoradiographic signals obtained with the other probes (data not shown).
To assess whether the apparent levels of c-erbB2 amplification were due to genuine amplification or due to an increase in the copy number of chromosome 17, on which the c-erbB2 gene lies (17q21-q22), the Southern blot filters were rehybridised with two probes from chromosome 17. These were a gastrin cDNA probe (localised to 17q) (Lund et al., 1986) (Figure 2c ) and a human growth hormone cDNA probe (17q22-q24) (Barsh et al., 1983 ; data not shown). These genes were present at single copy numbers in all cases, demonstrating that the c-erbB2 gene amplification observed was real and not due to an increase in the ploidy of chromosome 17.
Lymphocyte DNA was available for several of the patients whose tumours exhibited amplification of the c-erbB2 gene. Southern blot analysis of these tumour-lymphocyte pairs (Figure 1) showed that the amplifications (tumours 40, 64, 95) and the one rearrangement (tumour 80) observed were present only in the tumour DNA of that patient and not in the lymphocyte DNA, suggesting that these amplifications -10 kb -5.6 kb and rearrangement arose specifically in the breast tumour and were not a result of germline transmission.
Overexpression of c-erbB2 RNA in primary breast tumours Sixty-two human primary breast tumours were analysed for c-erbB2 mRNA expression by RNase mapping, using 32P-labelled RNA probes derived from the 3' non-coding region of the c-erbB2 gene. C-erbB2 transcripts were found to be overexpressed in 19 of the 62 tumour RNA samples mapped (30%) at levels ranging from 2 to 10-fold (Figure 2a) , relative to a sample of 'normal' breast RNA, quantitated by densitometry. In order to visualise weaker bands in tumour samples expressing low levels of c-erbB2 RNA, the autoradiograms were exposed for long periods. The bands in tumour samples which overexpress c-erbB2 RNA are therefore overexposed. The integrity of the RNA used had been confirmed in a previous study (Parkes et al., 1988) .
Of the 70 tumours from which RNA and/or DNA were isolated, there were 49 samples suitable for examination of both c-erbB2 DNA amplification and c-erbB2 RNA expression. In every case in which the c-erbB2 gene copy number was increased there was concomitant overexpression of cerbB2 RNA (Figure 2b and lb respectively). The increase in levels of c-erbB2 RNA was approximately proportional to the degree of amplification of the gene. However, in several cases (8/16) we observed overexpression of c-erbB2 RNA with no detectable accompanying amplification of the cerbB2 gene (Figure 2a, tumour 94 ). This suggests that there must be an additional mechanism(s), other than gene amplification, that can lead to deregulation of c-erbB2 mRNA expression. The RNase mapping experiments did not show any evidence of anomalies in the 3' ends of the breast tumour RNAs under investigation.
Localisation of c-erbB2 RNA within breast tumours by in situ hybridisation We employed in situ hybridisation (ISH) using 35S-labelled c-erbB2 cRNA probes to identify cells synthesising c-erbB2 RNA in paraffin-embedded, formalin-fixed breast tumour sections. The c-erbB2 cRNA localised specifically to tumour cells within the breast tissue sections (Figure 3a,b,c) . There was no significant hybridisation observed over normal breast tissue within the same sections (Figure 3a) , or in control sections processed in parallel but probed with 35S-labelled c-erbB2 mRNA probes (Figure 3d) .
We also investigated the possibility that the failure to detect c-erbB2 RNA overexpression in some tumour samples could be due to heterogeneity within the tumour cell population, allowing tumour cells with increased levels of c-erbB2 RNA to be 'overshadowed' by larger numbers of normal breast cells. As ISH detects expression of c-erbB2 RNA within individual cells, we could determine whether the tumour cells within a tissue section overexpressed c-erbB2 RNA even when overexpression of c-erbB2 RNA had not been detected using RNase mapping. We therefore carried out ISH with a 35S-labelled c-erbB2 cRNA probe on sections from six tumours, for which we had previously determined c-erbB2 RNA levels. Two tumours in which we detected no increase in c-erbB2 levels showed no intense hybridisation to tumour cells within the section (Figure 4a ). As expected, sections from the four tumours in which we had previously shown elevated levels of c-erbB2 showed strong hybridisation ( Figure 4b ). Again, parallel controls probed with a 35S-labelled cRNA probe showed no significant hybridisation.
Correlation between c-erbB2 DNA amplification and RNA overexpression and clinicopathologicalfeatures We used the x2 test for rectangular contingency tables to examine the association between increased levels of c-erbB2 and a variety of clinical parameters, in order to evaluate the potential role of c-erbB2 as a prognostic indicator in the pathogenesis of breast cancer (Tables I, II and III) .
When the correlation between c-erbB2 DNA amplification and disease recurrence was examined (Table I) (pB127) with increased c-erbB2 levels.
study (Table II) . However, we did not observe an association of any greater significance between higher levels of c-erbB2 gene amplification and disease recurrence or overall survival time.
In view of the fact that elevated c-erbB2 expression can occur in the absence of gene amplification, we have examined in greater detail the potential prognostic significance of (Table III) . There was, however, no significant correlation found between c-erbB2 RNA expression and other clinical features such as patient age or menopausal status and oestrogen and progesterone receptor status. No elevation of c-erbB2 RNA levels was observed in any of the infiltrating lobular carcinomas examined in this study (Table  III) , although this group of tumour type was small (7/62). Fifty-eight per cent of patients with increased c-erbB2 RNA expression had suffered a relapse, as compared with 42% for the population with 'normal' c-erbB2 RNA levels. When the disease-free interval was plotted against the percentage of patients with a recurrence, for both the normal and the elevated c-erbB2 RNA populations ( Figure 5 ), a slight trend was noted. However, this trend did not seem to be 0. associated specifically with short term relapse as has been observed by Varley et al. (1987) for c-erbB2 DNA amplification. The most significant correlation observed was between overexpressed c-erbB2 RNA and decreased overall survival time (P = 0.001) (Table I) . However, this association was determined on a very small sample number (six patients) and should therefore be confirmed using a larger series of breast tumours. Again, no more significant an association was observed between tumours with the highest elevation of c-erbB2 RNA levels and disease recurrence or survival (Table  II) .
As patients' prognoses may to some extent be dependent upon postoperative therapy, we took into account the adjuvant therapy received by patients when assessing the association between c-erbB2 expression and prognosis. Only five patients (7%) received adjuvant therapy. However, it is interesting to note that none of these cases had relapsed, although three had tumours with elevated c-erbB2 RNA levels. When these tamoxifen-treated patients were excluded from the disease recurrence study (Table I) , the trend towards an association between c-erbB2 levels and relapse approached significance (P = 0.05-0.1).
Discussion
In this study we have undertaken a comprehensive survey of both c-erbB2 gene amplification and mRNA overexpression within the same human primary breast tumours. We observed frequent increases in c-erbB2 gene copy number (17.5%). This result is in general agreement with the c-erbB2 gene amplification frequency observed by most other groups (Van de Vijver et al., 1987; Varley et al., 1987; Berger et al., 1988) , but lower than the figure of 40% given by Slamon et al. (1987) for his group of node positive patients. We also observed a rare rearrangement of the c-erbB2 gene in one of the tumours studied (1.7%). Slamon et al. (1987) noted a rearrangement in 1.6% of tumours studied. DiFiore et al. (1987) have demonstrated that the level of the c-erbB2 gene product is critical in determining its transforming ability in NIH 3T3 cells. Therefore quantitation of levels of c-erbB2 RNA expression in human breast carcinomas is of interest. In our comprehensive study we have investigated the level of c-erbB2 mRNA overexpression in 68 tumours by RNase mapping.
A significant difference was observed in the frequency of c-erbB2 mRNA overexpression (30%) compared with c-erbB2 gene amplification (17.5%) in the same tumour group. Although c-erbB2 gene copy amplification was always accompanied by an equivalent increase in c-erbB2 mRNA levels, we also observed increased expression of c-erbB2 mRNA in the absence of DNA amplification in some tumours. In a small scale study, of 11 primary breast carcinomas, of which only three had amplified c-erbB2 DNA, Van de Vijver et al. (1987) also found that amplification correlated with RNA overexpression. Kraus et al. (1987) Wright et al. (1989) have also supported the role of the c-erbB2 oncoprotein as a prognostic indicator. Other studies have been less conclusive (Zhou et al., 1989; Barnes et al., 1988 ; Van de Vijver et al., 1988) Our results suggest a trend towards an association of both c-erbB2 DNA amplification and RNA overexpression with decreased disease-free interval, although the correlation was not statistically significant (P = 0.1-0.05). However, in view of the frequency of overexpression of c-erbB2 RNA in breast carcinomas and the trends towards an association with poor prognosis noted by many authors, including ourselves, we believe that c-erbB2 does have a role to play in the neoplastic progression of breast cancer. The exact nature of this function, and whether it is a causal factor in the disease or an adaptive response, requires further investigation.
